• Anti Reverse Cap Analog in mRNA Translation

  2026-10-06

  Anti Reverse Cap Analog, 3´-O-Me-m7G(5')ppp(5')G, is examined here as a variable in the evidence chain linking synthetic mRNA capping, translation initiation, and therapeutic interpretation. The article connects ARCA chemistry with the targeted mRNA nanoparticle study in ACS Nano while separating product claims from peer-reviewed evidence.

• LG 101506 and the RXR–PD-L1 Evidence Gap

  2026-10-06

  LG 101506 is an RXR modulator that can support mechanistic research spanning nuclear receptor signaling, metabolism regulation, and tumor immunology. This article places the compound beside the RBMS1–PD-L1 findings in triple-negative breast cancer, clarifying what the study demonstrates, what remains hypothetical, and how chemical biology can test the connection.

• Dual HER2–VEGFR-2 Targeting in TNBC

  2026-10-05

  The 2026 reference study examines Lapatinib and Telatinib as a dual tyrosine kinase inhibition strategy in HER2-negative MDA-MB-231 triple-negative breast cancer cells. Its main contribution is phenotype-focused evidence linking treatment with reduced invadopodia formation, cell proliferation, and two-dimensional tube formation, while also showing why receptor-specific mechanisms require additional validation.

• FMO3–TMAO Signalling in Aging Adipose Dysfunction

  2026-10-05

  A 2024 Hong Kong Polytechnic University thesis proposes that adipose FMO3 is an important local contributor to TMAO accumulation and age-associated white adipose tissue dysfunction. Its multi-model findings connect adipocyte FMO3 to senescence, inflammation, fibrosis, and metabolic impairment, while also identifying a possible TMAO–ASC–NLRP3 mechanism that requires further validation.

• Dual HER2–VEGFR-2 Targeting in Breast Cancer

  2026-10-04

  The 2026 reference study examines Lapatinib and Telatinib as a phenotype-focused combination in HER2-negative MDA-MB-231 triple-negative breast cancer cells. Reduced proliferation, invadopodia formation, and two-dimensional angiogenic tube formation support further investigation, while the findings do not by themselves establish direct HER2 engagement or pharmacological synergy.

• Imatinib Hydrochloride: Five Evidence Questions

  2026-10-03

  A source-grounded overview of Imatinib hydrochloride, the principles behind kinase inhibition, and what a recent p38α dephosphorylation preprint does—and does not—show about mechanism, evidence quality, research scope, and limitations.

• Anlotinib in Desmoplastic Small Round Cell Tumors

  2026-10-02

  This case report describes radiographic lymph-node reduction and sustained clinical control in metastatic intra-abdominal desmoplastic small round cell tumor after treatment with anlotinib. Its main contribution is a clinically relevant signal for a rare malignancy, while the single-patient design limits conclusions about efficacy, dosing, and survival.

• From OA Biomarkers to Actionable ECL Validation

  2026-10-01

  A translational perspective on how acetylation-related osteoarthritis biomarkers move from bioinformatic discovery to experimentally defensible protein validation, with practical guidance for Western blot chemiluminescence detection and research-use ECL workflows.

• Miransertib C8430: Reliable Cell Assay Design

  2026-10-01

  Learn how to use Miransertib (SKU C8430) in a controlled, interpretable workflow for cell viability, proliferation, and cytotoxicity studies. The article combines practical assay design, numerical starting parameters, orthogonal validation, and candid vendor-selection criteria without inferring product-specific potency data that are not provided.

• Afatinib A4746 for Reliable Viability Assays

  2026-09-30

  This scenario-driven guide explains how Afatinib, SKU A4746, can improve experimental consistency in cell viability, proliferation, and cytotoxicity workflows. It connects ErbB-family biology with solvent handling, assay controls, assembloid design, and practical supplier-selection criteria.

• Patient-Derived Gastric Cancer Assembloids

  2026-09-30

  The reference study develops patient-derived gastric cancer assembloids by combining tumor organoids with matched stromal cell subpopulations. Its results show that stromal composition changes transcriptomic states and drug sensitivity, creating a more physiologically informative platform for tumor–stroma biology and personalized treatment research.

• Computational Saturation Mutagenesis Maps SHP2 Mutations

  2026-09-29

  The reference study uses computational saturation mutagenesis to evaluate more than 9,000 single-amino-acid substitutions across the SH2 and PTP domains of SHP2. By combining predicted binding-energy changes with functional assays and clinical annotation, it identifies conformational destabilization, particularly around A72 and G503, as a mechanistic route from PTPN11 variation to abnormal signaling and disease.

• WST-8 Glucose Uptake Assay Kit Workflow

  2026-09-29

  Build a non-radioactive glucose uptake workflow around the WST-8 Glucose Uptake Assay Kit for liver, cancer, and diabetes research. This guide connects quantitative 2-DG uptake with insulin resistance and autophagy questions while emphasizing calibration, normalization, and troubleshooting.

• Drug-Sensitized Yeast for mTOR Inhibitor Discovery

  2026-09-28

  A 2025 GeroScience study developed a genetically drug-sensitized yeast platform that detects TOR/mTOR pathway inhibitors at substantially lower concentrations than wild-type yeast. The system distinguishes TOR1-dependent growth inhibition from general toxicity and provides a practical screening framework, while finding no detectable TOR inhibition by nebivolol in this model.

• AMG 9810 for TRPV1 Assay Design

  2026-09-28

  Use AMG 9810 to distinguish TRPV1-dependent calcium and neuropeptide responses from broader effects of metabolic stress. This guide pairs practical antagonist workflows with a clear boundary: the cited AMPK–SQSTM1 study motivates parallel pathway measurements, not a presumed TRPV1 mechanism.

8387 records 1/560 page Next 12345 下5页 Last page